Overview
This is a prospective multicenter clinical study. This study aims to construct an auxiliary decision-making system for lung cancer immunotherapy combined with radiotherapy by fusing three modes of imagomics, clinicopathological features, and molecular pathological features.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years of age on day of signing informed consent
- Histopathology confirmed non-small cell lung cancer
- Asymptomatic brain metastases
- EGFR/ALK ROS1 driver gene mutation negative
- RECIST 1.1 based available assessment of lesions
- ECOG 0-1
- Brain metastases 1-4
- Single lesion ≤4cm
Exclusion Criteria:
- Patients with contraindication of chemotherapy Pregnant or breast feeding women